Kevin C. Gorman compensation by year
NEUROCRINE BIOSCIENCES Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $860,000 | $946,000 | $779,357 |
| Bonus | $989,000 | $1,040,600 | $1,141,950 |
| Stock awards | $5,125,079 | $7,021,386 | $7,000,139 |
| Option awards | $4,875,106 | $6,678,790 | $6,999,698 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | — | — |
| All other | $53,342 | $64,036 | $97,493 |
| Total | $11,902,527 | $15,750,812 | $16,018,637 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEUROCRINE BIOSCIENCES INC DEF 14A filed April 9, 2025, accession 0000914475-25-000091, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NEUROCRINE BIOSCIENCES INC filed document, accession 0000914475-25-000091. Every figure is read from that document and cited to the page and table it appears in. Filed April 9, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 50,979 | $6,958,634 | — |
| RSU | 28,686 | $3,915,639 | — |
| PSU | 26,576 | $3,627,624 | — |
| RSU | 22,415 | $3,059,648 | — |
| RSU | 16,130 | $2,201,745 | — |
| RSU | 10,283 | $1,403,630 | — |
| RSU | 4,318 | $589,407 | — |
| Option | 4,744 | — | $117.63 |
| Option | 37,930 | — | $79.02 |
| Option | 72,397 | — | $103.52 |
| Option | 89,176 | — | $133.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NEUROCRINE BIOSCIENCES INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
NEUROCRINE BIOSCIENCES’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Kevin C. Gorman · this page | Former Chief Executive Officer | $16,018,637 |
| Kyle W. Gano | Chief Executive Officer | $8,535,422 |
| Sanjay Keswani | Chief Medical Officer Jude Onyia, Ph.D. (8) Chief Scientific Officer | $7,035,851 |
| Jude Onyia | Chief Scientific Officer | $7,035,851 |
| Eiry W. Roberts | Chief Medical Officer | $6,764,318 |
| Matthew C. Abernethy | Chief Financial Officer | $6,595,201 |
| Eric Benevich | Chief Commercial Officer | $6,306,164 |
Board service
NEUROCRINE BIOSCIENCES board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,000 | $0 | $400,037 | $0 | $470,037 |
| FY2024 | — | — | — | — | — |
| FY2023 | $0 | $0 | $0 | — | — |
| FY2022 | $0 | — | $0 | — | — |
| FY2021 | $0 | — | $0 | — | — |
Each year as the company reported it in NEUROCRINE BIOSCIENCES's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: NEUROCRINE BIOSCIENCES pays directors a $60,000 cash retainer and $400,000 in RSUs/Options. As stated in NEUROCRINE BIOSCIENCES's FY2025 proxy.
Committees
Science and Medical Technology
The full NEUROCRINE BIOSCIENCES compensation record
free company briefThis page is one person within NEUROCRINE BIOSCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NEUROCRINE BIOSCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEUROCRINE BIOSCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.